Pałucha-Poniewiera Agnieszka, Rafało-Ulińska Anna, Faron-Górecka Agata, Pabian Paulina, Kaczorowska Katarzyna
Department of Neurobiology, Polish Academy of Sciences, Maj Institute of Pharmacology, 12 Smętna Street, 31-343, Kraków, Poland.
Department of Pharmacology, Maj Institute of Pharmacology, Polish Academy of Sciences, 12 Smętna Street, 31-343, Kraków, Poland.
Psychopharmacology (Berl). 2025 May 8. doi: 10.1007/s00213-025-06803-0.
(S)-Ketamine, which is used to treat depression, has significant undesirable effects and has potential for abuse. A safe alternative to (S)-ketamine is (R)-ketamine. The relationship between (R)-ketamine and the mGlu receptor is unknown, although screening tests indicate the possibility of potentiation of the antidepressant effect of (R)-ketamine by the mGlu receptor negative allosteric modulator (NAM).
We aimed to investigate whether the antidepressant-like effect of (R)-ketamine is mGlu receptor-dependent. Specifically, we investigated the possibility of enhancing (R)-ketamine antidepressant-like effects using the partial mGlu receptor NAM, 2-(2-(3-methoxyphenyl)ethynyl)-5-methylpyridine (M-5MPEP), in a chronic unpredictable mild stress (CUMS) model of depression in mice.
The effect of (R)-ketamine on mGlu receptor availability in the mouse brain was investigated using an autoradiographic method. Animal behaviors reflecting anhedonia, apathy, and helplessness were analyzed to study the rapid and sustained antidepressant-like effects of the combined administration of (R)-ketamine and M-5MPEP. Hippocampal protein levels were measured via Western blotting.
(R)-Ketamine altered mGlu receptor availability in several mouse brain regions. Importantly, in the hippocampus, (R)-ketamine reversed CUMS-induced effects. Behavioral studies revealed that M-5MPEP enhanced the effectiveness of a subeffective dose of (R)-ketamine. This drug combination effectively reduced CUMS-induced apathy- and anhedonia-like behavior symptoms. Changes in hippocampal eukaryotic elongation factor2 (eEF2) and tropomyosin receptor kinase B (TrkB) levels accompanied these effects.
The weakening of mGlu receptor function in the hippocampus appears to be related to the (R)-ketamine antidepressant-like effect, and coadministration of the partial mGlu receptor NAM, M-5MPEP, might increase its antidepressant activity.
用于治疗抑郁症的(S)-氯胺酮具有显著的不良作用且有滥用潜力。(R)-氯胺酮是(S)-氯胺酮的一种安全替代物。尽管筛选试验表明代谢型谷氨酸受体(mGlu)负变构调节剂(NAM)可能增强(R)-氯胺酮的抗抑郁作用,但(R)-氯胺酮与mGlu受体之间的关系尚不清楚。
我们旨在研究(R)-氯胺酮的抗抑郁样作用是否依赖于mGlu受体。具体而言,我们在小鼠慢性不可预测轻度应激(CUMS)抑郁模型中,研究了使用部分mGlu受体NAM 2-(2-(3-甲氧基苯基)乙炔基)-5-甲基吡啶(M-5MPEP)增强(R)-氯胺酮抗抑郁样作用的可能性。
采用放射自显影法研究(R)-氯胺酮对小鼠脑内mGlu受体可用性的影响。分析反映快感缺失、冷漠和无助的动物行为,以研究(R)-氯胺酮与M-5MPEP联合给药的快速和持续抗抑郁样作用。通过蛋白质免疫印迹法测量海马蛋白水平。
(R)-氯胺酮改变了小鼠几个脑区的mGlu受体可用性。重要的是,在海马体中,(R)-氯胺酮逆转了CUMS诱导的效应。行为学研究表明,M-5MPEP增强了亚有效剂量(R)-氯胺酮的有效性。这种药物组合有效减轻了CUMS诱导的冷漠和快感缺失样行为症状。这些效应伴随着海马真核生物延伸因子2(eEF2)和原肌球蛋白受体激酶B(TrkB)水平的变化。
海马体中mGlu受体功能的减弱似乎与(R)-氯胺酮的抗抑郁样作用有关,部分mGlu受体NAM M-5MPEP的联合给药可能会增加其抗抑郁活性。